Biogen Price Target Maintained With a $292.00/Share by RBC Capital
Biogen Analyst Ratings
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $292
RBC Capital analyst Brian Abrahams maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $292.According to TipRanks data, the analyst has a success rate of 49.7% and a
RBC Capital Keeps Their Buy Rating on Biogen (BIIB)
Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)
Express News | Biogen Exec Says if FDA's Review for Subcutaneous Leqembi Is Expedited Approval Could Come After 8 Months From Submission Vs 12 Months